Growing questions about marijuana smoking and cancer risk
While a growing body of research suggests a link between heavy marijuana smoking and cancer risk, there remains many unanswered questions. – Image credit Keck Medicine at USC CANCER DIGEST – July 26, 2026 – With marijuana being legalized in more states, questions about health and safety remain, and a growing body of research is showing that heavy marijuana smoking may raise the risk of lung cancer and several types of head and neck cancers. Nevertheless, even as preliminary i
Could a vaccine prevent pancreatic cancer?
A small clinical trial showed proof of concept of vaccine prevention of pancreatic cancer in high-risk individuals. (Image generated by WIX AI) CANCER DIGEST – July 19, 2026 – That’s the question asked by researchers led by Neeha Zaidi, MD, at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. Approximately 10 percent of pancreatic cancers are associated with genetic predisposition caused by mutations in specific cancer susceptibility genes that are pa
Half of prostate cancer patients have treatment plan changed following 2nd PSMA-PET scan
A second PSMA-PET scan for both local and distant prostate cancer resulted in a change in treatment for nearly 50 percent of prostate cancer patients following initial treatment.
Breakthrough drug daraxonrasib doubles survival in patients with advanced pancreatic cancer
In a clinical trial, an experimental oral targeted medication nearly doubled overall survival in pancreatic cancer patients with a specific genetic mutation, compared to standard chemotherapy.
FDA approves IBRANCE® for triple positive breast cancer
The complex interactions of hormone receptors often can result in treatment resistance for patients with HR+ and HER2+ advanced breast cancer. – Image credit Penn Medicine. CANCER DIGEST – June 27, 2026 – The U.S. Food and Drug Administration has approved the targeted drug palbociclib in combination with standard therapies for adult patients with hormone receptor-positive (HR+) and HER2-positive (HER2+) often called triple positive locally advanced or metastatic breast cancer
GLP-1 drugs tied to lower breast cancer incidence in large study
Women who used GLP-1 medications were about 30 percent less likely to develop breast cancer than similar women who did not use the drugs, according to a new retrospective study led by researchers at University of Pennsylvania
